CNS drug development: Part II: Advances from the 1960s to the 1990s
about
sameAs
Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning.A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia.Determination of blood concentration levels of psychotropic medications in Rwandan patients.
P2860
CNS drug development: Part II: Advances from the 1960s to the 1990s
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
CNS drug development: Part II: Advances from the 1960s to the 1990s
@ast
CNS drug development: Part II: Advances from the 1960s to the 1990s
@en
CNS drug development: Part II: Advances from the 1960s to the 1990s
@nl
type
label
CNS drug development: Part II: Advances from the 1960s to the 1990s
@ast
CNS drug development: Part II: Advances from the 1960s to the 1990s
@en
CNS drug development: Part II: Advances from the 1960s to the 1990s
@nl
altLabel
CNS Drug Development
@en
prefLabel
CNS drug development: Part II: Advances from the 1960s to the 1990s
@ast
CNS drug development: Part II: Advances from the 1960s to the 1990s
@en
CNS drug development: Part II: Advances from the 1960s to the 1990s
@nl
P1476
CNS Drug Development
@en
CNS drug development: Part II: Advances from the 1960s to the 1990s
@en
P2093
Sheldon H Preskorn
Sheldon H. Preskorn
P356
10.1097/01.PRA.0000390760.12204.99
P407
P577
2010-11-01T00:00:00Z